Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

Withdrawn

• Conditions: Adrenergic Pathology
• Interventions: Drug: Administration of 123Iodine MIBG

• Registration Number: NCT01912040
• Lead Sponsor: Nova Scotia Health Authority

Brief Summary

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Detailed Description

We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Study Timeline

• Study Start: 2006-07
• Status Verified: 2013-07
• Study First Submitted: 2013-07-12
• Study First Submitted QC: 2013-07-29
• Study First Posted: 2013-07-30
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Last Update Submitted: 2022-11-09
• Last Update Posted: 2022-11-14

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with potential Adrenergic pathology

Exclusion Criteria

• Pregnant or breast feeding females
• Hypersensitivity to MIBG

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients	Administration of 123Iodine MIBG	Administration of 123Iodine MIBG to the patients referred .

Primary Outcome Measures

Name	Time	Method
Safety profile of the 123Iodine MIBG	BP and Heart rate for 24 hours after injection.

Trial Locations

Locations (1)

Capital District Health Authority; 🇨🇦 Halifax, Nova Scotia, Canada